The Memorandum of Understanding (MOU) formalizes the company’s relationship with the Asan Medical Center's (AMC) Clinical Trial Center and its principal investigators.
The contract research organization (CRO) will help augment AMC’s clinical research capabilities internationally, and in turn, the center will provide professional and medical advice to Novotech for clinical trials conducted at the facility, including feasibility, principal investigator selection, and patient recruitment.
Novotech CEO Dr. John Moller told us the company has worked with AMC since it opened its Korea operation in 2008.
"Novotech will work closely with the ASAN to ensure that we have early discussions with the Clinical Trial Centre and Key Opinion Leaders about projects that may be appropriate to Korea," he said.
"The MOU also means that the most senior individuals in each organization will have closer direct access to one another and the two organizations will work to ensure rapid engagement and high priority start-up of new projects," Moller added.
Dr. Young Suk Lim, director of the South Korea-based medical institution, commented that the AMC is committed to “increasing and expanding” its medical and technology infrastructure.
As Outsourcing-Pharma.com previously reported, the CRO market in Asia is expected to grow significantly through 2020.